Document is current
Any future updates will be listed below
-
Authors
Schiattarella, Gabriele G. https://orcid.org/0000-0002-7582-7171
Alcaide, Pilar
Condorelli, Gianluigi
Gillette, Thomas G.
Heymans, Stephane https://orcid.org/0000-0001-9477-7803
Jones, Elizabeth A. V. https://orcid.org/0000-0002-2006-7064
Kallikourdis, Marinos https://orcid.org/0000-0001-9318-3368
Lichtman, Andrew https://orcid.org/0000-0002-3546-058X
Marelli-Berg, Federica https://orcid.org/0000-0001-8747-5823
Shah, Sanjiv J. https://orcid.org/0000-0002-5655-8201
Thorp, Edward B. https://orcid.org/0000-0003-1387-7058
Hill, Joseph A. https://orcid.org/0000-0002-5379-1614
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
- License Information
-
More Information
Article History
Received: 6 October 2021
Accepted: 2 February 2022
First Online: 14 March 2022
Competing interests
: S.J.S. has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. All the other authors declare no competing interests.
